Half‐life extended factor VIII for the treatment of hemophilia A

Publisher： John Wiley & Sons Inc

E-ISSN： 1538-7836|13|S1|S176-S179

ISSN： 1538-7933

Source： JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol.13, Iss.S1, 2015-06, pp. : S176-S179

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Role of enhanced half‐life factor VIII and IX in the treatment of haemophilia

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 6, 2015-06 ,pp. : 768-776

John Wiley & Sons Inc

Access to resources Recommend Favorite

Transition considerations for extended half‐life factor products

By  

HAEMOPHILIA, Vol. 21, Iss. 3, 2015-05 ,pp. : 285-288

John Wiley & Sons Inc

Access to resources Recommend Favorite

Recombinant full‐length factor VIII (FVIII) and extended half‐life FVIII products in prophylaxis – new insight provided by pharmacokinetic modelling

By  

HAEMOPHILIA, Vol. 21, Iss. 3, 2015-05 ,pp. : 300-306

John Wiley & Sons Inc

Access to resources Recommend Favorite

Author's response: ‘Transition considerations for extended half‐life factor products’

By  

HAEMOPHILIA, Vol. 1351-8216, Iss. 5, 2015-09 ,pp. : e454-e455

John Wiley & Sons Inc

Access to resources Recommend Favorite

Author's response: ‘Transition considerations for extended half‐life factor products’

By  

HAEMOPHILIA, Vol. 21, Iss. 5, 2015-09 ,pp. : e454-e455

John Wiley & Sons Inc

Access to resources Recommend Favorite